Inovio Pharmaceuticals (INO) is a risky buy
Inovio Pharmaceuticals (INO) currently trades at $7.82 and has grown by 4% today. The catalyst of the moment is the COVID-19 virus pandemic. Inovio is one of the multiple companies racing to develop vaccines and antiviral treatments for the COVID-19 virus.
Based on this information, investorsQ rates this stock 4 out of 10. We give it this rating based on current information. Inovio has been receiving a significant amount of grant money as it prepares to bring its COVID-19 vaccine, INO-4800, to trial. The company received a $5 million grant from the Bill & Melinda Gates Foundation and a $9 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI). The high forecast for Inovio Pharmaceuticals is $13.00 and the low is $7.00. Notably, the company’s market cap is $1.15 billion with a 52 week high of $19.36 and a 52 week low of $1.92.